Market Cap
$7.5M
KALA
KALA BIO, Inc.
$0.3884 ▼ -7.30%
Prev close $0.4190Market cap$7.5M
High Impact Filing (8/10) Biotech & Drug Discovery
Snapshot
The big-picture read on KALA right now — valuation, ownership and activity at a glance.
Cap Size
Nano Cap
Inst. Holders
11 funds
Inst. Value
$1.2M
Social Sentiment
50° Neutral
SEC Reports
4
Press Releases
1
Price chart 30d -25.7%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 24, 2026 contract
Aug 28, 2026 SEC Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a select
KALA BIO received a delisting notice from Nasdaq on August 27, 2026, because its stock closed below $1.00 for 30 consecu
8-K — Impact 8/10
KALA BIO filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $250,000,000 in common
424B5 — Impact 8/10
KALA BIO's shelf registration (File No. 333-295667) became effective on June 25, 2026, allowing the company to conduct o
EFFECT — Impact 7/10
KALA BIO announced a strategic initiative to become a dedicated AI infrastructure provider for the biotech industry by d
Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 29, 2025 | HC Wainwright & Co. | DOWNGRADE | Neutral | 43% |
| Sep 17, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Sep 11, 2025 | Oppenheimer | MAINTAIN | Outperform | 52% |
| Sep 8, 2025 | Mizuho | INITIATE | Outperform | 52% |
| May 23, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Apr 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Feb 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Nov 15, 2024 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 19, 2024 | Oppenheimer | REITERATE | Outperform | 52% |
| May 17, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Aug 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jul 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Jun 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| May 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Apr 1, 2026 | 0 | 0 | 3 | 1 | 2 | 0% | |
| Mar 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% | |
| Feb 1, 2026 | 0 | 0 | 4 | 1 | 2 | 0% |
Social media sentiment mood +25.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 0 bullish, 3 bearish, 0 mixed, 1 neutral · avg impact 6.3/10.Plus 1 press releases.
BEARISH8-K8/10
KALA BIO received a delisting notice from Nasdaq on August 27, 2026, because its stock closed below
Aug 28, 2026
BEARISH424B58/10
KALA BIO filed a 424B5 prospectus supplement for an at-the-market (ATM) equity offering of up to $25
Jul 22, 2026
BEARISHEFFECT7/10
KALA BIO's shelf registration (File No. 333-295667) became effective on June 25, 2026, allowing the
Jun 26, 2026
NEUTRALS-32/10
KALA BIO filed an S-3 shelf registration to issue an unlimited amount of senior and subordinated deb
May 7, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 24, 2026
contract
Kala Bio and Virotek Sign Letter of Intent with U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
Agreement would expand the companies' genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an ad
Sep 17, 2026
other
KALA BIO Adds Healthcare Operator Yenvy Truong to Advisory Team
Founder of The LSM Group to support KALA's growth across its existing business and potential acquisitions Founder of The LSM Group to support KALA's g
Sep 4, 2026
listing_status
Listing Status: KALA — Deficient (was Normal)
KALA BIO, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Aug 28, 2026
trading_halt
Halt Resumed: KALA — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-28T13:38:45.000Z | Resumed 2026-08-28T13:43:45.000Z
Aug 28, 2026
trading_halt
Trading Halt: KALA — LUDP (Volatility Trading Pause)
KALA BIO, Inc. Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next Q | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Current FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
| Next FY | $0.00 | $0.00–$0.00 | — | — | — | $0.0B | — |
Institutional ownership
Which big funds own KALA (from quarterly 13F filings) and who is adding or trimming.
11 institutional holders with $1.2M total value (700,576 shares) as of 2026-Q2. Top holders: VANGUARD, GEODE, VANGUARD.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 220,623 | $381.7K | 31.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 145,152 | $251.1K | 20.7% | — |
| VANGUARD FIDUCIARY TRUST CO | 101,396 | $175.4K | 14.5% | — |
| STATE STREET CORP | 88,570 | $153.2K | 12.6% | — |
| BlackRock, Inc. | 71,542 | $123.8K | 10.2% | — |
| NORTHERN TRUST CORP | 41,606 | $72.0K | 5.9% | — |
| Qube Research & Technologies Ltd | 11,073 | $19.2K | 1.6% | — |
| GOLDMAN SACHS GROUP INC | 10,921 | $18.9K | 1.6% | — |
| UBS Group AG | 9,057 | $15.7K | 1.3% | — |
| BARCLAYS PLC | 608 | $1.1K | 0.1% | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for KALA.
Shares short
445,421
Settlement Sep 15, 2026
Change vs prior
+10.5%
Semi-monthly cycle
Days to cover
1.0
At avg daily volume
Of shares outstanding
≈2.3%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Aug 28, 2026 | LUDP | Volatility Pause | Resumed |
All KALA filing & press-release reports (5)
- 8-K reportAug 28, 2026
- 424B5 reportJul 22, 2026
- EFFECT reportJun 26, 2026
- S-3 reportMay 7, 2026
- PRESS-RELEASE reportMar 4, 2026